Guardant Health, Flatiron Health Launch Platform Integration Initiative
Companies aim to simplify access to informative patient care data.
Guardant Health, a precision oncology company, and Flatiron Health, a health tech company, announced an initiative to integrate Guardant’s genomic profiling tests within Flatiron’s OncoEMR, a cloud-based electronic medical record (EMR) tool. Reportedly, the integration simplifies access to critical data that informs patient care decisions for over 2,000 clinicians within the Flatiron network, which includes more than 800 community-based cancer care locations across the US.
“Genomic profiling provides critical data that helps oncologists make timely and informed decisions about personalized treatment plans for their patients,” said Chris Freeman, chief commercial officer, Guardant Health. “This integration with the OncoEMR platform, which reaches almost 40 percent of U.S. community oncologists, will simplify access to our tests and enable a significant step forward in our mission to conquer cancer with data.”
Reference: Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform. BusinessWire. October 31, 2023. Accessed October 31, 2023. https://www.businesswire.com/news/home/20231031158337/en/Guardant-Health-Flatiron-Health-Announce-Integration-of-Guardant-Genomic-Profiling-Tests-Into-OncoEMR%C2%AE-Platform
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
